These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 23154587)

  • 1. The angiotensin II type 1 receptor blocker olmesartan preferentially improves nocturnal hypertension and proteinuria in chronic kidney disease.
    Yanagi M; Tamura K; Fujikawa T; Wakui H; Kanaoka T; Ohsawa M; Azushima K; Maeda A; Kobori H; Umemura S
    Hypertens Res; 2013 Mar; 36(3):262-9. PubMed ID: 23154587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Olmesartan medoxomil and azelnidipine therapy in patients with hypertension and chronic kidney disease in Japan.
    Saito I; Kushiro T; Zenimura N; Matsushita Y; Sagawa K; Hiramatsu K; Yamaguchi F
    J Nephrol; 2012; 25(5):699-708. PubMed ID: 22020401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of direct renin inhibitor and angiotensin II receptor blocker on clinic and ambulatory blood pressure profiles in hypertension with chronic kidney disease.
    Uneda K; Tamura K; Wakui H; Azushima K; Haku S; Kobayashi R; Ohki K; Haruhara K; Kinguchi S; Ohsawa M; Fujikawa T; Umemura S
    Clin Exp Hypertens; 2016; 38(8):738-743. PubMed ID: 27936941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced blood pressure-lowering effect of olmesartan in hypertensive patients with chronic kidney disease-associated sympathetic hyperactivity: HONEST study.
    Kario K; Saito I; Kushiro T; Teramukai S; Mori Y; Hiramatsu K; Kobayashi F; Shimada K
    J Clin Hypertens (Greenwich); 2013 Aug; 15(8):555-61. PubMed ID: 23889717
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beneficial effect of aliskiren combined with olmesartan in reducing urinary protein excretion in patients with chronic kidney disease.
    Moriyama T; Tsuruta Y; Kojima C; Itabashi M; Sugiura H; Takei T; Ogawa T; Uchida K; Tsuchiya K; Nitta K
    Int Urol Nephrol; 2012 Jun; 44(3):841-5. PubMed ID: 21626132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of combination olmesartan medoxomil plus azelnidipine versus monotherapy with either agent on 24-hour ambulatory blood pressure and pulse rate in Japanese patients with essential hypertension: additional results from the REZALT study.
    Shimada K; Ogihara T; Saruta T; Kuramoto K;
    Clin Ther; 2010 May; 32(5):861-81. PubMed ID: 20685495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 24-hour and nighttime blood pressures in type 2 diabetic hypertensive patients following morning or evening administration of olmesartan.
    Tofé Povedano S; García De La Villa B
    J Clin Hypertens (Greenwich); 2009 Aug; 11(8):426-31. PubMed ID: 19695030
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urinary angiotensin-converting enzyme 2 in hypertensive patients may be increased by olmesartan, an angiotensin II receptor blocker.
    Furuhashi M; Moniwa N; Mita T; Fuseya T; Ishimura S; Ohno K; Shibata S; Tanaka M; Watanabe Y; Akasaka H; Ohnishi H; Yoshida H; Takizawa H; Saitoh S; Ura N; Shimamoto K; Miura T
    Am J Hypertens; 2015 Jan; 28(1):15-21. PubMed ID: 24842388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How important is it to control nocturnal hypertension with angiotensin II type 1 receptor blockers?
    Miura S; Saku K
    Hypertens Res; 2013 Mar; 36(3):194-5. PubMed ID: 23171955
    [No Abstract]   [Full Text] [Related]  

  • 10. Olmesartan vs. ramipril in elderly hypertensive patients: review of data from two published randomized, double-blind studies.
    Omboni S; Malacco E; Mallion JM; Fabrizzi P; Volpe M
    High Blood Press Cardiovasc Prev; 2014 Mar; 21(1):1-19. PubMed ID: 24435506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension.
    White WB; Weber MA; Sica D; Bakris GL; Perez A; Cao C; Kupfer S
    Hypertension; 2011 Mar; 57(3):413-20. PubMed ID: 21282560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of effects of angiotensin II receptor blocker on morning home blood pressure and cardiorenal protection between morning administration and evening administration in hypertensive patients: the COMPATIBLE study.
    Mori H; Yamamoto H; Ukai H; Yuasa S; Nakajima K; Mikawa T; Niizuma M; Hirao K; Umemura S;
    Hypertens Res; 2013 Mar; 36(3):202-7. PubMed ID: 23013888
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Olmesartan/amlodipine: a review of its use in the management of hypertension.
    Kreutz R
    Vasc Health Risk Manag; 2011; 7():183-92. PubMed ID: 21490944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of angiotensin II type 1 receptor blocker on ambulatory blood pressure variability in hypertensive patients with overt diabetic nephropathy.
    Masuda S; Tamura K; Wakui H; Kanaoka T; Ohsawa M; Maeda A; Dejima T; Yanagi M; Azuma K; Umemura S
    Hypertens Res; 2009 Nov; 32(11):950-5. PubMed ID: 19713965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of antihypertensive therapy with add-on angiotensin II type 1 receptor blocker after successful coronary stent implantation.
    Sugihara M; Miura S; Takamiya Y; Kiya Y; Arimura T; Iwata A; Kawamura A; Nishikawa H; Uehara Y; Saku K
    Hypertens Res; 2009 Jul; 32(7):625-30. PubMed ID: 19461652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Difference in the effects of switching from candesartan to olmesartan or telmisartan to olmesartan in hypertensive patients with type 2 diabetes: the COTO study.
    Daikuhara H; Fukunaga K; Ohshima T
    Drug Des Devel Ther; 2014; 8():219-26. PubMed ID: 24600204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of valsartan on progression of kidney disease in Japanese hypertensive patients with advanced, predialysis, chronic kidney disease: Kanagawa Valsartan Trial (KVT).
    Yasuda T; Endoh M; Suzuki D; Yoshimura A; Ideura T; Tamura K; Kamata K; Toya Y; Umemura S; Kimura K;
    Hypertens Res; 2013 Mar; 36(3):240-6. PubMed ID: 23154591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of multiple factorial intervention on ambulatory BP profile and renal function in hypertensive type 2 diabetic patients with overt nephropathy - a pilot study.
    Kanaoka T; Tamura K; Moriya T; Tanaka K; Konno Y; Kondoh S; Toyoda M; Umezono T; Fujikawa T; Ohsawa M; Dejima T; Maeda A; Wakui H; Haku S; Yanagi M; Mitsuhashi H; Ozawa M; Okano Y; Ogawa N; Yamakawa T; Mizushima S; Suzuki D; Umemura S
    Clin Exp Hypertens; 2011; 33(4):255-63. PubMed ID: 21699452
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Olmesartan medoxomil-based antihypertensive therapy evaluated by ambulatory blood pressure monitoring: efficacy in high-risk patient subgroups.
    Chrysant SG; Germino FW; Neutel JM
    Am J Cardiovasc Drugs; 2012 Dec; 12(6):375-89. PubMed ID: 23116225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study.
    Imai E; Chan JC; Ito S; Yamasaki T; Kobayashi F; Haneda M; Makino H;
    Diabetologia; 2011 Dec; 54(12):2978-86. PubMed ID: 21993710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.